
<DOC>
<DOCNO>
WSJ900822-0041
</DOCNO>
<DOCID>
900822-0041.
</DOCID>
<HL>
   Business Brief -- Unilabs Holdings S.A.:
   Unilab Holder Plans to Buy
   Regional Roche Operations
</HL>
<DATE>
08/22/90
</DATE>
<SO>
WALL STREET JOURNAL (J), PAGE C10
</SO>
<CO>
   ULAB Z.HR
</CO>
<IN>
TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)
</IN>
<LP>
   Unilab Corp., New York, said its majority shareholder
Unilabs Holdings S.A. of Geneva signed a letter of intent to
buy the western regional operations of Roche Biomedical
Laboratories Inc.
   Unilab officials said the decision reflects a long-held
company strategy to concentrate on the West Coast market.
Under the agreement, Unilab will acquire Roche's Sacramento
and Denver operations. The assets include clinical,
anatomical and cytology testing businesses, as well as
facilities and staff. The operations being purchased
represent annual sales of about $40 million. The purchase
price is approximately $41 million.
</LP>
<TEXT>
   Roche, a subsidiary of New Jersey-based Hoffmann-La Roche
Inc., is one of the nation's largest clinical laboratory
networks. Hoffmann-La Roche in turn is a unit of Roche
Holding Ltd., Basel, Switzerland.
   As part of the transaction with Unilab, Roche will
maintain its own specialty testing businesses in such areas
as substance abuse and paternity and bone marrow
identification programs.
   Upon completion of the transaction, Unilab's combined
revenue is expected to be in excess of $170 million.
</TEXT>
</DOC>